Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Cash from Financing Activities (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Cash from Financing Activities for 15 consecutive years, with -$979000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities fell 1155.13% to -$979000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$31.1 million, a 144.72% decrease, with the full-year FY2024 number at $9.6 million, up 167.1% from a year prior.
  • Cash from Financing Activities was -$979000.0 for Q3 2025 at Usana Health Sciences, up from -$38.6 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $22.9 million in Q4 2024 to a low of -$122.4 million in Q1 2022.
  • A 5-year average of -$16.6 million and a median of -$3.2 million in 2023 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: crashed 26356.82% in 2023, then skyrocketed 3384.8% in 2024.
  • Usana Health Sciences' Cash from Financing Activities stood at -$70.5 million in 2021, then surged by 99.79% to -$150000.0 in 2022, then skyrocketed by 538.67% to $658000.0 in 2023, then surged by 3384.8% to $22.9 million in 2024, then crashed by 104.27% to -$979000.0 in 2025.
  • Per Business Quant, the three most recent readings for USNA's Cash from Financing Activities are -$979000.0 (Q3 2025), -$38.6 million (Q2 2025), and -$14.5 million (Q1 2025).